What amount sold does Reshape Medical, Inc. report in Form D filings?

The latest linked filings report $75.1M sold across 5 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Reshape Medical, Inc.'s most recent SEC filing?

Reshape Medical, Inc.'s most recent Form D filing was on 2017-02-13.

How many investors does Reshape Medical, Inc. have?

The most recent Form D filing lists 10 investor(s).

What type of securities does Reshape Medical, Inc. offer?

Reshape Medical, Inc.'s SEC Form D filings indicate debt offerings.

Reshape Medical, Inc.

CIK: 0001410930·Biotechnology·SAN CLEMENTE, CA·Corporation

Reported Sold

$75,072,648

Total Filings

Identified Offerings

Last Filed

Feb 13, 2017

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Feb 13, 2017Form D — New notice

Reported sold: $11,000,000 · Target: $11,000,000

Rule 506(b)·10 investors

Sep 2, 2015Form D — New notice

Reported sold: $37,999,991 · Target: $37,999,991

Rule 506(b)·10 investors

Mar 19, 2015Form D/A — Amendment

Reported sold: $8,750,000 · Target: $8,750,000

Rule 506(b)·7 investors

Changed: Reported amount sold, Offering target

Feb 4, 2015Form D/A — Amendment

Reported sold: $6,750,000 · Target: $6,750,000

Rule 506(b)·7 investors

Changed: Reported amount sold, Offering target

Dec 11, 2014Form D/A — Amendment

Reported sold: $5,250,000 · Target: $5,250,000

Rule 506(b)·7 investors

Changed: Reported amount sold, Offering target

Jul 8, 2014Form D — New notice

Reported sold: $4,000,000 · Target: $4,000,000

Rule 506(b)·7 investors

Oct 19, 2012Form D — New notice

Reported sold: $15,822,657 · Target: $21,447,655

Rule 506·7 investors

Jun 6, 2012Form D — New notice

Reported sold: $1,500,000 · Target: $3,000,000

Rule 506·7 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

38%

Latest reported sold across 5 identified offerings

$75,072,648

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Bruce Feuchter

Related Person

Appears on 6 filings

Kenneth Charhut

Related Person

Appears on 6 filings

Jeani Delagardelle

Related Person

Appears on 6 filings

David Milne

Related Person

Appears on 6 filings

Casey Tansey

Related Person

Appears on 6 filings

John Lehmann, M.D.

Related Person

Appears on 6 filings

Richard Thompson

Related Person

Appears on 5 filings

Eric Milledge

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Feb 13, 2017	New	$11,000,000	$11,000,000	10
Sep 2, 2015	New	$37,999,991	$37,999,991	10
Mar 19, 2015	Amendment	$8,750,000	$8,750,000	7
Feb 4, 2015	Amendment	$6,750,000	$6,750,000	7
Dec 11, 2014	Amendment	$5,250,000	$5,250,000	7
Jul 8, 2014	New	$4,000,000	$4,000,000	7
Oct 19, 2012	New	$21,447,655	$15,822,657	7
Jun 6, 2012	New	$3,000,000	$1,500,000	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Adela, Inc.

Biotechnology

Offering target: $12,000,000

Filed Oct 19, 2026